Renal-hepatic-pancreatic dysplasia 1

disease
On this page

Also known as NPHP3 renal-hepatic-pancreatic dysplasiarenal-hepatic-pancreatic dysplasia caused by mutation in NPHP3renal-hepatic-pancreatic dysplasia type 1RHPD1

Summary

Renal-hepatic-pancreatic dysplasia 1 (MONDO:0008833) is a disease with 3 cohort genes.

At a glance

  • Cohort genes: 3
  • ClinVar variants: 386

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namerenal-hepatic-pancreatic dysplasia 1
Mondo IDMONDO:0008833
OMIM208540
UMLSC3715199
MedGen811626
GARD0018431
Is cancer (heuristic)no

Also known as: NPHP3 renal-hepatic-pancreatic dysplasia · renal-hepatic-pancreatic dysplasia 1 · renal-hepatic-pancreatic dysplasia caused by mutation in NPHP3 · renal-hepatic-pancreatic dysplasia type 1 · RHPD1

Data availability: 386 ClinVar variants.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary diseaserenal-hepatic-pancreatic dysplasiarenal-hepatic-pancreatic dysplasia 1

Related subtypes (1): renal-hepatic-pancreatic dysplasia 2

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

386 retrieved; paginated sample, class counts are floors:

229 uncertain significance, 62 conflicting classifications of pathogenicity, 28 likely benign, 19 pathogenic/likely pathogenic, 17 likely pathogenic, 15 benign/likely benign, 12 pathogenic, 4 benign

ClinVarVariant (HGVS)GeneClassificationReview
1706521NM_153240.5(NPHP3):c.69del (p.Gly24fs)LOC129937586Pathogenicno assertion criteria provided
1069581NM_153240.5(NPHP3):c.3402_3403del (p.Ala1135fs)NPHP3Pathogeniccriteria provided, multiple submitters, no conflicts
1454636NM_153240.5(NPHP3):c.469del (p.Arg157fs)NPHP3Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
195423NM_153240.5(NPHP3):c.434_437del (p.Glu145fs)NPHP3Pathogeniccriteria provided, multiple submitters, no conflicts
2021418NM_153240.5(NPHP3):c.1675del (p.His559fs)NPHP3Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
220868NM_153240.5(NPHP3):c.2694-2_2694-1delNPHP3Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2632NM_153240.5(NPHP3):c.3821GAG[1] (p.Gly1275del)NPHP3Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2634NM_153240.5(NPHP3):c.1381G>T (p.Glu461Ter)NPHP3Pathogeniccriteria provided, multiple submitters, no conflicts
2638NM_153240.5(NPHP3):c.3340C>T (p.Gln1114Ter)NPHP3Pathogeniccriteria provided, single submitter
2640NM_153240.5(NPHP3):c.2104C>T (p.Arg702Ter)NPHP3Pathogeniccriteria provided, multiple submitters, no conflicts
3383107NM_153240.5(NPHP3):c.3357_3379dup (p.Leu1127delinsProTer)NPHP3Pathogeniccriteria provided, single submitter
462725NM_153240.5(NPHP3):c.1985+1G>ANPHP3Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
571434NM_153240.5(NPHP3):c.2956dup (p.Gln986fs)NPHP3Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
812666NM_153240.5(NPHP3):c.520-1G>TNPHP3Pathogeniccriteria provided, multiple submitters, no conflicts
936828NM_153240.5(NPHP3):c.2851C>T (p.Arg951Ter)NPHP3Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
96511NM_153240.5(NPHP3):c.2369T>C (p.Leu790Pro)NPHP3Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
996537NM_153240.5(NPHP3):c.2805C>T (p.Gly935=)NPHP3Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1029229NM_153240.5(NPHP3):c.2570+1G>TNPHP3-ACAD11Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1454640NM_153240.5(NPHP3):c.3775C>T (p.Arg1259Ter)NPHP3-ACAD11Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
216136NM_153240.5(NPHP3):c.1817G>A (p.Trp606Ter)NPHP3-ACAD11Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2634638NM_153240.5(NPHP3):c.3812+2dupNPHP3-ACAD11Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
499565NM_153240.5(NPHP3):c.2311-2A>GNPHP3-ACAD11Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
500889NM_153240.5(NPHP3):c.634dup (p.Glu212fs)NPHP3-ACAD11Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
571559NM_153240.5(NPHP3):c.2563C>T (p.Gln855Ter)NPHP3-ACAD11Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
597322NM_153240.5(NPHP3):c.1101_1102insATTTTATTATT (p.His368fs)NPHP3-ACAD11Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
635041NM_153240.5(NPHP3):c.1174C>T (p.Arg392Ter)NPHP3-ACAD11Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
693989NM_153240.5(NPHP3):c.3619C>T (p.Arg1207Ter)NPHP3-ACAD11Pathogeniccriteria provided, multiple submitters, no conflicts
848816NM_153240.5(NPHP3):c.958-2A>GNPHP3-ACAD11Pathogeniccriteria provided, multiple submitters, no conflicts
853024NM_153240.5(NPHP3):c.3003del (p.Phe1001fs)NPHP3-ACAD11Pathogeniccriteria provided, multiple submitters, no conflicts
96516NM_153240.5(NPHP3):c.3373C>T (p.Arg1125Ter)NPHP3-ACAD11Pathogeniccriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
NPHP3Orphanet:294415Renal-hepatic-pancreatic dysplasia
NPHP3Orphanet:3032NPHP3-related Meckel-like syndrome
NPHP3Orphanet:3156Senior-Loken syndrome
NPHP3Orphanet:93589Late-onset nephronophthisis
NPHP3Orphanet:93591Infantile nephronophthisis

Cohort genes → proteins

3 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence3

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
NPHP3-AS1HGNC:24129ENSG00000248724NPHP3 antisense RNA 1clinvar
NPHP3-ACAD11HGNC:48351ENSG00000274810NPHP3-ACAD11 readthrough (NMD candidate)clinvar
NPHP3HGNC:7907ENSG00000113971Q7Z494Nephrocystin-3clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
NPHP3Nephrocystin-3Required for normal ciliary development and function.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown31.8×0.174

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
NPHP3-AS1Other/Unknownno
NPHP3-ACAD11Other/Unknownno
NPHP3Other/UnknownnoTPR-like_helical_dom_sf, TPR_rpt, P-loop_NTPase

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)3
unknown0

Top tissues across cohort

TissueCohort genes
male germ line stem cell (sensu Vertebrata) in testis2
secondary oocyte1
sural nerve1
calcaneal tendon1
endometrium1
layer of synovial tissue1
left ovary1
superficial temporal artery1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
NPHP3-AS159markersural nerve, secondary oocyte, male germ line stem cell (sensu Vertebrata) in testis
NPHP3-ACAD11133tissue_specificyesmale germ line stem cell (sensu Vertebrata) in testis, calcaneal tendon, endometrium
NPHP3254ubiquitousmarkersuperficial temporal artery, layer of synovial tissue, left ovary

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
NPHP32,275
NPHP3-AS10
NPHP3-ACAD110

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 2

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
NPHP3Q7Z4941

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 3 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Trafficking of myristoylated proteins to the cilium12284.0×4e-04NPHP3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
determination of intestine left/right asymmetry116852.0×7e-04NPHP3
determination of stomach left/right asymmetry116852.0×7e-04NPHP3
convergent extension involved in gastrulation18426.0×9e-04NPHP3
convergent extension15617.3×9e-04NPHP3
determination of pancreatic left/right asymmetry13370.4×9e-04NPHP3
maintenance of animal organ identity13370.4×9e-04NPHP3
regulation of Wnt signaling pathway, planar cell polarity pathway13370.4×9e-04NPHP3
determination of liver left/right asymmetry12808.7×9e-04NPHP3
ureter development12808.7×9e-04NPHP3
atrial septum development12106.5×0.001NPHP3
kidney morphogenesis11872.4×0.001NPHP3
epithelial cilium movement involved in determination of left/right asymmetry11296.3×0.002NPHP3
establishment or maintenance of cell polarity1401.2×0.005NPHP3
photoreceptor cell maintenance1358.6×0.005NPHP3
non-motile cilium assembly1290.6×0.006NPHP3
heart looping1267.5×0.006NPHP3
determination of left/right symmetry1255.3×0.006NPHP3
lung development1198.3×0.007NPHP3
kidney development1140.4×0.009NPHP3
extracellular matrix organization1122.1×0.010NPHP3
negative regulation of canonical Wnt signaling pathway1117.8×0.010NPHP3
Wnt signaling pathway199.7×0.011NPHP3
lipid metabolic process191.6×0.011NPHP3
cilium assembly173.6×0.014NPHP3

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 3

Druggability breadth: 0 of 3 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
NPHP3-AS100
NPHP3-ACAD1100
NPHP300

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug3NPHP3-AS1, NPHP3-ACAD11, NPHP3

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
NPHP3-AS10
NPHP3-ACAD110
NPHP30

Clinical trials & evidence

Clinical trials

Clinical trials: 0.